Zepbound vs Wegovy: Which Costs Less in 2026?

TL;DR

• Without insurance, Zepbound costs roughly $1,000 to $1,500 per month and Wegovy costs about $1,300 to $1,600, but self-pay options from both manufacturers now bring costs as low as $199 to $499 per month.
• With commercial insurance that covers medication, both offer copay cards that can reduce your cost to as little as $25 per month.
• Zepbound showed greater average weight loss in a head-to-head study (20.2% vs 13.7%), but Wegovy has FDA-approved cardiovascular benefits and a new oral pill option.

What Does Zepbound Cost Without Insurance?

Zepbound (tirzepatide) is made by Eli Lilly. At full retail price, a month's supply of Zepbound pens costs approximately $1,000 to $1,500 depending on dose and pharmacy.

However, Eli Lilly has introduced lower-cost single-dose vials available directly through their LillyDirect program. These vials require you to draw medication into a syringe yourself (instead of using a pre-filled pen), but savings are significant. As of early 2026, vial pricing through LillyDirect is:

• 2.5 mg: $299 per month
• 5 mg: $399 per month
• 7.5 mg, 10 mg, 12.5 mg, or 15 mg: $499 per month

These prices are available to anyone paying out of pocket, regardless of insurance status. This has made Zepbound one of more accessible options for people whose insurance does not cover weight loss medications.

If you do have commercial insurance that covers Zepbound, Zepbound Savings Card can bring your out-of-pocket cost down to as little as $25 per month. This applies to eligible patients with qualifying commercial plans. It does not apply to government-funded insurance like Medicare, Medicaid, or Tricare.

What Does Wegovy Cost Without Insurance?

Wegovy (semaglutide) is made by Novo Nordisk. The retail price for Wegovy injection pens is approximately $1,300 to $1,800 per month, depending on dose.

Novo Nordisk has also stepped in with self-pay pricing to compete. Through NovoCare Pharmacy program, cash-paying and uninsured patients can get Wegovy at reduced rates. As of early 2026, self-pay pricing for injectable is:

• Starting doses (0.25 mg and 0.5 mg): $199 per month for first two months
• Maintenance doses: $349 per month

A major development for Wegovy happened in late 2025 when FDA approved an oral tablet version of semaglutide for weight loss. This pill launched in January 2026 and is priced at $149 per month for starting doses and $299 per month for maintenance dose of 25 mg. For people who do not want weekly injections, this is a meaningful alternative.

With commercial insurance that covers Wegovy, Novo Nordisk's savings program can reduce costs significantly as well, with some patients paying as little as $0 to $25 per month depending on their plan.

How Does Insurance Coverage Compare?

This is where things get complicated, because insurance coverage for weight loss medications varies widely from plan to plan and even from year to year.

Wegovy has been on market longer (FDA-approved in 2021 vs 2023 for Zepbound), which means it has had more time to get onto insurance formularies. Some plans that cover Wegovy do not yet cover Zepbound. On other hand, some pharmacy benefit managers have shifted their preferred coverage toward Zepbound in certain plan designs.

In 2024, Wegovy gained a major boost when FDA approved it for reducing risk of heart attack, stroke, and cardiovascular death in adults with heart disease and obesity or overweight. This cardiovascular indication has opened doors for insurance coverage that would not have been available for weight management alone. Some Medicare Advantage plans and certain commercial plans now cover Wegovy specifically for this heart-related indication.

Zepbound received its own additional FDA approval in 2024 for treating moderate-to-severe obstructive sleep apnea in adults with obesity. This can also help with insurance coverage if you have a documented sleep apnea diagnosis.

The bottom line on insurance: call your plan directly and ask whether each medication is covered, what copay or coinsurance would be, and whether prior authorization is required. Many plans require you to try one before covering other, so order in which you and your provider pursue coverage can matter.

For a closer look at whether specific insurance plans cover Zepbound, this guide breaks it down: Does Anthem Cover Zepbound for Weight Loss?

Side-by-Side Cost Comparison

Here is a simplified overview of what you might expect to pay for each medication in different scenarios:

Without any insurance or savings programs:

• Zepbound: $1,000 to $1,500 per month (pens)
• Wegovy: $1,300 to $1,800 per month (pens)

With manufacturer self-pay programs (no insurance):

• Zepbound vials via LillyDirect: $299 to $499 per month
• Wegovy injection via NovoCare: $199 to $349 per month
• Wegovy oral tablet: $149 to $299 per month

With qualifying commercial insurance + savings card:

• Zepbound: As low as $25 per month
• Wegovy: As low as $0 to $25 per month

Medicare and Medicaid:

• As of 2026, Medicare and Medicaid generally do not cover weight loss medications. There may be limited exceptions based on specific diagnoses like cardiovascular disease (for Wegovy) or sleep apnea (for Zepbound).

Beyond Cost: How Do They Compare Clinically?

Cost is a huge factor, but it should not be only thing guiding your decision. These medications have some meaningful clinical differences.

Zepbound (tirzepatide) works by activating two hormone receptors: GIP and GLP-1. This dual-receptor approach appears to produce greater average weight loss. In a head-to-head trial published in The New England Journal of Medicine in 2025, participants on Zepbound lost an average of 20.2% of their body weight over 72 weeks, compared to 13.7% for those on Wegovy. That is roughly 50 pounds versus 33 pounds on average.

Wegovy (semaglutide) activates only GLP-1 receptor. While average weight loss is somewhat lower than Zepbound, Wegovy has something Zepbound does not yet have: proven cardiovascular benefits. The SELECT trial showed that Wegovy reduced risk of heart attack, stroke, and cardiovascular death by 20% in adults with heart disease and obesity. That data earned Wegovy its cardiovascular indication from FDA.

Both medications share similar side effects, primarily nausea, diarrhea, vomiting, and constipation. These tend to be most noticeable during dose escalation phase and generally improve over time.

Neither medication is "better" in every situation. Your medical history, insurance coverage, tolerance for side effects, and personal preferences all play into which one makes more sense for you.

If you want to compare Zepbound with another weight loss injection option, this resource may be helpful: Saxenda vs Zepbound

Will Prices Drop in Future?

There are several reasons to expect gradual cost improvements for both medications over next few years, though dramatic drops are unlikely in near term.

Neither Zepbound nor Wegovy has a generic version available. Both are protected by patents, and generic competition is likely still years away. However, compounded versions of tirzepatide and semaglutide were temporarily available during drug shortages, and this has put pressure on manufacturers to offer competitive self-pay pricing.

More employers are expected to add GLP-1 coverage to their health plans in 2026. Surveys suggest that over a quarter of large employers may cover these medications for obesity, up from about one-fifth in 2025. As coverage expands, more people will have access to low-copay savings card prices rather than paying full retail.

The introduction of oral Wegovy in early 2026 also changes landscape. At $149 to $299 per month, it is substantially cheaper than injectable versions of either drug and removes barrier of self-injection entirely. If you are someone who dislikes needles, this could be deciding factor.

FDA Drug Approvals and Safety Information

How to Save Most on Either Medication

No matter which medication you and your doctor choose, there are a few practical steps that can help you pay less.

Start by checking your insurance formulary. Your plan may cover one but not other, or may cover both with different copay tiers. Knowing this upfront saves time and frustration.

Apply for manufacturer savings card before your first fill. Both Eli Lilly and Novo Nordisk offer these programs, and they can dramatically reduce your copay if you have eligible commercial insurance.

If you are uninsured or your plan does not cover either drug, go straight to self-pay options. LillyDirect for Zepbound vials or NovoCare for Wegovy can cut your monthly cost by 50% to 80% compared to retail pricing.

Ask your provider about prior authorization. Many insurance plans require it, and a well-documented submission from your doctor can make difference between a denial and approval. If your first request is denied, appeal it. Many denials are overturned on appeal.

Consider oral Wegovy tablet if injections are a barrier. The lower price point and convenience of a daily pill instead of a weekly injection may make it easier to stay consistent with treatment.

Conclusion

Zepbound and Wegovy are both effective, FDA-approved weight loss medications, but they differ in cost, insurance coverage, clinical benefits, and available formats. At full retail, Wegovy is slightly more expensive, but manufacturer self-pay programs have brought both medications into a more accessible price range. With insurance and savings cards, either can cost as little as $25 per month.

The best choice depends on your specific health needs, your insurance situation, and what your provider recommends based on your medical history. If cardiovascular protection matters, Wegovy has stronger data. If maximum weight loss is priority, Zepbound has edge in clinical trials. And if cost without insurance is deciding factor, both manufacturers are now offering competitive self-pay pricing that was not available even a year ago.